셀젠바이오테크
  • >>
  • Surpport
  • >>
  • 제품 자료
제품 자료

[셀젠바이오테크: Nanostring] nCounter PanCancer Immune Profiling Panel

본문

 

A Multiplexed Gene Expression Approach To Profiling Cancer Immunology

The nCounter PanCancer Immune Profiling Panel is a novel new gene expression panel that enables researchers to develop profiles of the human immune response in all cancer types. In collaboration with cancer immunologists around the globe, our new 770 gene panel combines markers for 24 different immune cell types and populations, 30 common cancer antigens and genes that represent all categories of immune response including key checkpoint blockade genes.

  • Explore Infiltrating Cell Types
  • Understand Immune Pathway Activity
  • Create Profiles of the Immune Response in Any Cancer Type

PanCancer Immune Diagram

  • 109 genes to cell surface markers for 24 different immune cell types and populations
  • 30 genes for commonly studied CT Antigens
  • Over 500 genes for measuring immune response
  • 40 Reference Genes (including 30 overlapping controls with the PanCancer Pathways Panel)
  • Customize with the addtion of up to 30 genes with our Panel-Plus feature

Use Cases

  • Use Case 1
  • Use Case 2
  • Use Case 3

Selecting Adjuvants to Support Adoptive T Cell Therapy

Dr. Martin McIntosh, Fred Hutchinson Cancer Research Center

A growing number of cancer patients will be offered some type of adoptive T cell therapy, especially after conventional therapies fail3. Some patients have experienced dramatic improvements following T cell therapy, but many patients, even those whose tumors possess the target antigen, have not. Response rates could be improved by modulating the tumor microenvironment toward a state that is more supportive of immune function, and a number of existing tools can do this to some degree4,5; including cytokines, interleukins, interferons, checkpoint blockade (PD-1/PD-L1, BTLA-4, etc.), and others. Effective modulation strategies may require developing a molecular toolkit (assays and algorithms) that can accurately assess factors that are actionable and is practical for use in a clinical setting.

We plan to use the PanCancer Immune Profiling Panel to identify which actionable factors can be measured adequately using nucleic acid-based assays, with the goal to develop a parsimonious companion diagnostic for T cell therapies. This may be challenging for many reasons, including that solid tumors vary in ways that can confound appropriate interpretation, e.g. variations in both the cellular composition and in the expression level of specific cells in it. To start, we would profile tissues whose cellular composition and immune-environment has also been measured by gold-standard assays such as IHC, and also by clinically impractical flow cytometry, including tissues from patients who are enrolled in T cell therapy trials.

3 Pedrazzoli P, Comoli P, Montagna D, Demirer T, Bregni M. (2012) Is adoptive T-cell therapy for solid tumors coming of age? Bone Marrow Transplant 47:1013–1019.
4 Tey SK, Bollard CM, Heslop HE (2006) Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol 84:281–289. 

5 Dougan M, Dranoff G. (2009) Immune therapy for cancer. Annu Rev Immunol 27:83–117. 

  • ㈜셀젠바이오테크, 대표자명: 김성빈, 사업자등록번호: 344-08-00018
  • 대전광역시 유성구 대학로 27, 유성현대리조텔 509호(305-301)
  • 대표전화: 042-824-9026 팩스: 042-824-9027
  • E-Mail: celgen-bio@celgen-bio.com
  • Copyright © 2015 Celgen-Bio.tech All rights reserved.